2021
Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group
Weinberg OK, Chisholm KM, Ok CY, Fedoriw Y, Grzywacz B, Kurzer JH, Mason EF, Moser KA, Bhattacharya S, Xu M, Babu D, Foucar K, Tam W, Bagg A, Orazi A, George TI, Wang W, Wang SA, Arber DA, Hasserjian RP. Clinical, immunophenotypic and genomic findings of NK lymphoblastic leukemia: a study from the Bone Marrow Pathology Group. Modern Pathology 2021, 34: 1358-1366. PMID: 33526873, DOI: 10.1038/s41379-021-00739-4.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAcute undifferentiated leukemiaWhite blood cellsLymphoblastic leukemiaAcute leukemiaBone Marrow Pathology GroupHigher white blood cellEvent-free survivalNatural killer cellsClinical outcome dataNative immune systemMore frequent expressionAUL patientsFree survivalAmbiguous lineageOverall survivalCytoplasmic CD3Leukemia groupClinical presentationHLA-DRKiller cellsPlatelet countProvisional entityCD10 expressionMyeloid leukemia
2018
Microenvironment Cell Contribution to Lymphoma Immunity
Kumar D, Xu ML. Microenvironment Cell Contribution to Lymphoma Immunity. Frontiers In Oncology 2018, 8: 288. PMID: 30101129, PMCID: PMC6073855, DOI: 10.3389/fonc.2018.00288.Peer-Reviewed Original ResearchLymphoma-associated macrophagesMesenchymal stem/stromal cellsT cellsLymphoma microenvironmentStromal cellsMarkers of exhaustionImmune checkpoint blockadeRegulatory T cellsEra of immunotherapyNatural killer cellsAnti-tumor effectsStem/stromal cellsLymphoma immunityTim-3Adverse eventsCheckpoint blockadeDendritic cellsImmune dysfunctionKiller cellsPD-1Immune cellsMechanisms of resistanceImmune escapeTumor surveillanceLAG-3